Search Videos and More

Showing 61 - 72 of 817 results

Previous| 1... 5 | 6 | 7 ...69 |Next


ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer Video

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.
2026 ASCO Bladder Cancer Highlights Video

2026 ASCO Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates
ASCO26: Sara Tolaney, MD, MPH, ASCENT-03 Video

ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.
ASCO26: David Reardon, MD, Glioblastoma Vaccine Video

ASCO26: David Reardon, MD, Glioblastoma Vaccine

Dana-Farber Cancer Institute's Dr. David Reardon reports on data showing a phase 1 trial looking at a personalized vaccine plus pembrolizumab sparked tumor-targeting T cells in glioblastoma and was linked to longer survival in immune responders.
ASCO26: Toni Choueiri, MD, KEYNOTE-654 Video

ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.
ASCO26: Alicia Morgans, MD, MPH, ARACOG Video

ASCO26: Alicia Morgans, MD, MPH, ARACOG

Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.
ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101 Video

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.
ASCO26: Sara Tolaney, MD, MPH, ASCENT-04 Video

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.
2026 ASCO Prostate Cancer Highlights Video

2026 ASCO Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates.
2026 ASCO Kidney Cancer Highlights Video

2026 ASCO Kidney Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates
ASCO26: Michael Hassett, MD, MPH, eSyM Video

ASCO26: Michael Hassett, MD, MPH, eSyM

Dr. Michael Hassett of Dana-Farber Cancer Institute shared new findings showing deployment of eSyM, an ePRO-based, EHR-integrated symptom management program, was associated with statistically significant and potentially meaningful improvements in overall survival. Strategies to improve adoption of ePRO-based symptom management may be warranted.
ESMO Breast Cancer 2026 Highlights: SERENA-6 Video

ESMO Breast Cancer 2026 Highlights: SERENA-6

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH discuss results from the SERENA-6 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

Showing 61 - 72 of 817 results

Previous| 1... 5 | 6 | 7 ...69 |Next